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Abstract
We synthesized “mesoscale” nanoparticles, approximately 400 nm in diameter, which 
unexpectedly localized selectively in renal proximal tubules and up to 7 times more efficiently in 
the kidney than other organs. Although nanoparticles typically localize in the liver and spleen, 
modulating their size and opsonization potential allowed for stable targeting of the kidneys 
through a new proposed uptake mechanism. Applying this kidney targeting strategy, we anticipate 
use in the treatment of renal disease and the study of renal physiology.
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Several kidney diseases may benefit from the development of nanoparticle therapeutics that 
allow for the site-directed accumulation, controlled temporal release, and protection of a 
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therapeutic payload.1–3 Among candidate diseases are lupus, glomerulonephritis, and renal 
cell carcinoma (RCC), which often arises in the proximal tubules.4–8 Pharmacological 
therapeutic options for these diseases are limited, thus it is necessary to increase the efficacy 
and decrease side effects of current drugs.9,10
To target specific sites in the body, investigators have taken advantage of specific 
physiological parameters that enhance delivery to disease sites, including the enhanced 
permeability and retention (EPR) effect to localize nanoparticles in tumors.11 In human 
patients, the EPR effect has not yet been shown to result in significant targeting, however, 
possibly due to low accumulation in small tumors and disseminated disease.12,13 Recently, 
investigators have invested in the “active” targeting of disease sites via functionalization of 
nanoparticles with a molecular recognition moiety such as an antibody, small molecule or 
aptamer.13 This general approach has generated positive preclinical results, some of which 
have progressed to clinical trials.13
Often, and sometimes irrespective of a molecular targeting element, nanoparticles may 
localize in one of several organs due to the particle surface chemistry, size, and zeta 
potential.14,15 The purposeful application of this mechanism may allow for the treatment of 
diseases regardless of the expression of molecular targets or the size of a lesion. The 
delivery of targeted agents to specific organs and tissues may obviate off-target effects in 
systemic delivery such as neutropenia or GI toxicity.1,16 To employ this targeting approach, 
it is necessary to understand the properties of nanoparticles that cause differential 
biodistribution in specific organs and cell types.
To investigate the parameters that may influence nanoparticle localization, we probed the 
literature and constructed a simple plot to consolidate nanoparticle localization data from 
multiple studies (Figure 1). We noted the major organ to which the nanoparticles localized 
as well as the nanoparticle size and the relative degree to which the particle may be 
opsonized by serum proteins, a natural process that labels exogenous materials for 
phagocytic destruction by the mononuclear phagocyte system (MPS).14 Avoidance of MPS-
mediated phagocytosis was achieved by nanoparticles with “stealth”, or nonopsonizing, 
materials such as polyethylene glycol (PEG) or natural lipoproteins.17,18 According to our 
noncomprehensive survey of the literature, the majority of untargeted nanoparticles 
primarily accumulate in the liver or spleen. The selective targeting to other organs, including 
the kidneys or lymph nodes, is rare, although it appears to require a relatively lowopsonizing 
surface chemistry.19,20
Nanomaterial size has a demonstrated effect on biodistribution. Certain synthetic polymers, 
low-molecular weight proteins, and peptides less than 20 kDa in molecular weight exhibit 
renal tubule biodistribution but are quickly cleared from the body.21,22 Nanoparticles less 
than 250 nm tend to accumulate in the liver or spleen, either through MPS trafficking or 
entrance through liver fenestrations (approximately 100 nm) (Figure 1). Microparticles 
(particles with diameters above 1000 nm) often localize in the lungs due to entrapment in 
pulmonary capillary beds.23–25 Mesoscale nanoparticles refer to the larger gamut of 
nanoparticles above 100 nm in diameter.26,27 To date, the long-term biodistribution and 
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tissue localization of mesoscale nanoparticles greater than 250 nm have not been studied in 
depth.
Herein, we synthesized mesoscale nanoparticles (MNPs) that avoid MPS organs to 
selectively and stably accumulate in the kidneys up to 7 times more efficiently than other 
organs. We determined the parameter space required for this localization in terms of particle 
size and opsonization potential. The nanoparticles accumulated in proximal versus distal 
renal tubules and more so at their basal rather than the apical membranes. We propose a 
mechanism in which MNPs are endocytosed by endothelial cells of the peritubular 
capillaries because of the pressure drop in the nephron and the large absorptive pressure of 
the capillaries. Applying this targeting strategy, we anticipate that mesoscale nanoparticles 
could be used to treat diseases that affect the proximal tubules of the kidneys and to study 
renal blood flow.
Nanoparticle Synthesis, Characterization, and Biodistribution Studies
Poly(lactic-co-glycolic acid) conjugated to polyethylene glycol (PLGA–PEG) was 
synthesized similarly to previously described methods with modifications.28 Carboxylic 
acid-terminated poly(lactic-co-glycolic acid) (PLGA) (50:50; MW 38–54 kDa) (90–130 
µmol) (Aldrich; St. Louis, MO) was dissolved in 10 mL of methylene chloride and activated 
with N-hydroxysuccinimide (NHS, 135 mg, 1.2 mmol) (Aldrich) and 1-ethyl-3-(3-
(dimethylamino)propyl)-carbodiimide (EDC, 230 mg, 1.2 mmol) for 30 min with stirring. 
Conjugated PLGA-NHS was precipitated with 5 mL of ethyl ether, washed 3× with cold 
50:50 ethyl ether/methanol, and dried under vacuum. To PLGA-NHS (1g, 18–26 µmol) in 4 
mL of chloroform, 250 mg (50 µmol) of NH2-PEG-COOH (MW 5 kDa) (Nanocs; New 
York, NY) was added with 28 mg (220 µmol) of N,N-diisopropylethylamine. After the 
reaction proceeded with mixing overnight, conjugated PLGA–PEG was precipitated and 
washed 3× with 5 mL of cold methanol and allowed to dry under vacuum. The polymer was 
characterized by 1H NMR as previously described.28
PLGA–PEG was used to form anionic mesoscale nanoparticles (A-MNPs) by the nano-
precipitation method similarly to as previously described with modifications.28 PLGA–PEG 
(100 mg) was dissolved with the fluorescent Cy5 mimic 3,3′-diethylthiadicarbocyanine 
iodide (DEDC) (Acros Organics; Geel, Belgium) (10 mg) in 2 mL acetonitrile. This solution 
was added dropwise to 4 mL of water with 100 µL of 10% Pluronic F-68 (Gibco; Grand 
Island, NY) and stirred for 2 h. The solution was then centrifuged for 15 min at 6600 rpm, 
washed, and centrifuged again. Particles were lyophilized in a 2% sucrose solution for 
storage at −20 °C. Dried particles were suspended in phosphate-buffered saline (PBS) or 
water and analyzed for size by dynamic light scattering (DLS) (Malvern; Worcestershire, 
United Kingdom) and scanning electron microscopy (SEM) following gold–palladium 
coating (Zeiss; Oberkochen, Germany), for ζ-potential by electrophoretic light scattering 
(ELS) (Malvern), and for encapsulation by UV–vis absorbance (Jasco; Easton, MD) and 
DEDC fluorescence (Tecan; Mannedorf, Switzerland). To synthesize cationic mesoscale 
nanoparticles (C-MNPs), 9.5 mg of lyophilized A-MNPs were suspended in a 1 mL solution 
of 0.5 mg/mL of didodecyldimethylammonium bromide (DMAB) as previously 
described.29,30 This method was used by others to modify an anionic PLGA–PEG 
Williams et al. Page 3













nanoparticle surface, resulting in cationic nanoparticles functionally shown to be stable for 
in vitro and in vivo applications.31–33 Before use, both A-MNPs and C-MNPs were 
centrifuged and resuspended in PBS to remove unincorporated dye and/or DMAB.
All experiments performed in animals were approved by and carried out in accordance with 
the MSKCC Institutional Animal Care and Use Committee. Female 4–8 week SKH-1 Elite 
hairless mice (Crl:SKH1-Hrhr) (Charles River; Troy, NY) were used in order to reduce 
background autofluorescence or absorbance from haired mice. They were fed irradiated 5 
V75 alfalfa-free food (LabDiet; St. Louis, MO) to reduce fluorescent background in 
imaging. Groups of six mice each were injected intravenously via the tail vein with 50 
mg/kg of A-MNPs or CMNPs encapsulating DEDC. Control groups of four mice each were 
injected with 100 µL of PBS or 23 µg/kg of DEDC in PBS with 0.5% DMSO (equal to the 
amount of encapsulated dye in particle-injected mice), as has been previously 
performed.25,34–36 Mice were imaged dorsally with an IVIS Spectrum Preclinical In vivo 
Imaging System (PerkinElmer; Waltham, MA) using 640 nm excitation and 680 nm 
emission filters to determine fluorescence biodistribution at the following times 
postinjection: 30 min, 4 h, and 1–7 days. In vivo fluorescence images were analyzed using 
Living Image Software v4.3 (PerkinElmer) with regions of interest (ROIs) selected around 
each kidney and the central lung region to obtain total fluorescence efficiency (TFE) from 
each. On day 3, three mice from the A-MNP and C-MNP groups, two mice from the PBS 
control group, and all four mice from the DEDC control group were euthanized by carbon 
dioxide overdose. The following organs were harvested and imaged for fluorescence: heart, 
lungs, kidneys, liver, and spleen. TFE for each organ was obtained and normalized by organ 
weight to obtain organ-level biodistribution. Normalized organ fluorescence for each group 
was averaged and standard deviations obtained. The organs were weighed and fixed with 
4% paraformaldehyde (PFA) overnight at 4 °C. One mouse treated with anionic nano-
particles was imaged by fluorescence and X-ray computed tomography (CT) with an IVIS 
Spectrum CT (PerkinElmer) 1 day following injection. Three-dimensional reconstruction of 
fluorescent foci around the kidneys was performed with multiple imaging fields and overlaid 
onto a computed tomographic image of the mouse in order to confirm kidney localization 
and determine particle distribution throughout the organ.
Fixed organs were dehydrated and paraffin embedded before 5 µm sections were placed on 
glass slides. The paraffin was removed and the slides were stained with hematoxylin and 
eosin (H&E) for basic histology. Another set of slides for immunofluorescence were stained 
with 4′,6-diamidino-2-phenylindole (DAPI) to stain nuclei of cells and either an anti-CD31 
antibody to stain endothelial cells (Dianova, Cat # DIA-310) with concentration of 1 µg/mL 
or anti-E-cadherin (BD Bioscience; San Jose, CA; Cat# 610181) with concentration of 5 
µg/mL to stain epithelial cells. For detection, isotype-specific secondary antibodies 
conjugated to AlexaFluor 488 (Invitrogen; Carlsbad, CA; Cat # T20922) were used at 
1:1000 dilution according to manufacturer’s instruction. Immunohistochemistry was 
performed using a Discovery XT processor (Ventana Medical Systems; Tuscon, AZ). The 
tissue sections were deparaffinized with EZPrep buffer (Ventana Medical Systems), antigen 
retrieval was performed with CC1 buffer (Ventana Medical Systems) and sections were 
blocked for 30 min with 10% normal rabbit serum in PBS + 0.1% BSA. Anti-PEG (Abcam; 
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Cambridge, MA; Cat # ab94764, 5ug/mL) antibodies specific to the PEG backbone were 
applied and sections were incubated for 5 h, followed by a 60 min incubation with 
biotinylated rabbit antirat IgG (Vector Laboratories; Burlingame, CA; Cat # PK-4004) at 
1:200 dilution. The assay was performed with a DAB detection kit (Ventana Medical 
Systems) according to manufacturer instructions. Slides were counterstained with 
hematoxylin (Ventana Medical Systems) and coverslipped with Permount (Fisher Scientific; 
Hampton, New Hampshire).
Slides were imaged with an Olympus IX51 inverted light microscope with slide adapter 
(Olympus; Center Valley, PA) outfitted with an Olympus DP73 digital color camera and 
Olympus XM10 monochrome camera. Fluorescent slides were excited with filtered light 
from a X-Cite 120Q lamp (Lumen Dynamics; Ontario, Canada). Fluorescence images were 
acquired with appropriate filter cubes for DAPI, AlexaFluor 488, and Cy5 with constant 
exposure times for each fluorophore and analyzed in ImageJ (National Institutes of Health; 
Bethesda, MD) with constant brightness values for each.
Results and Discussion
We synthesized anionic (A-MNPs) and cationic (C-MNPs) mesoscale nanoparticles, which 
both measured approximately 400 nm in diameter, from poly(lactic-co-glycolic acid) 
(PLGA) functionalized with PEG. The nanoparticles were loaded with a fluorescent dye for 
biodistribution studies. Carboxylic acid-terminated PLGA was conjugated to 
heterobifunctional amine-PEG-carboxylic acid. 1H NMR was performed to confirm 
conjugation. The nanoprecipitation method was used to form A-MNPs of 386.7 nm in 
diameter with a ζ-potential of −19.5 mV as determined by dynamic light scattering (DLS) 
and electrophoretic light scattering (ELS), respectively (Table 1, Supporting Information 
Figure S1a). We confirmed size and spherical morphology by scanning electron microscopy 
(SEM) (Figure 2a,b). Discrepancy in sizes as measured by SEM and DLS is attributable to 
shrinkage of the polymer upon drying and differences between dry and hydrodynamic 
diameters, the latter of which is measured by DLS.37–39 Didodecyldimethylammonium 
bromide (DMAB) was introduced form C-MNPs measuring 402.8 nm in diameter with a 
18.3 mV ζ-potential. Both particle formulations encapsulated 2.2 µg 3,3′-
diethylthiadicarbocyanine iodide (DEDC) fluorescent dye per 1 mg of nanoparticles. 
Additionally, the total fluorescence from each nanoparticle formulation was essentially 
identical (Supporting Information Figure S1b).
In order to explore nanoparticle stability, we performed aggregation, dye release, and ζ-
potential assays. Each particle formulation exhibited similar stability after incubation in PBS 
for 3 days as shown by particle size measurements (Figure 2c).40–42 Both nanoparticles were 
stable in storage conditions for at least 3 days as measured in PBS and in serum for up to 48 
h in 100% fetal bovine serum (FBS), at which point they began to aggregate. Upon 
introducing FBS, both cationic and anionic nanoparticles reached approximately the same ζ-
potential, which has been observed previously (Figure 2d).43 Finally, dye release assays 
showed similar release kinetics in PBS and FBS (Figure 2e).
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The nanoparticles selectively accumulated in the kidneys of mice following intravenous 
injection. We injected 50 mg/kg of A- or C-MNPs into female SKH-1 mice and imaged the 
animals daily for up to 7 days and biweekly thereafter for approximately 3 months. 
Biodistribution was measured by fluorescence in vivo in order to track nanoparticle 
localization and degradation over time, a widely used method that closely approximates 
other biodistribution assays.44–47 Mice treated with MNPs showed no significant weight loss 
compared to mice treated with dye alone (Supporting Information Figure S2). Nanoparticles 
localized to both kidneys and the chest region (Figure 3a, Supporting Information Figure 
S3). Upon organ extraction, to obtain more quantitative biodistribution patterns, we 
examined fluorescence in various organs; the fluorescence signal was significantly greater in 
the kidneys than in any other organ analyzed (Figure 3b). The fluorescence emission from 
the kidneys was greatest at day 3 for C-MNP-treated mice: 5.3 times greater than the next-
highest organ, the heart, for A-MNPs and 5.9 times for C-MNPs at day 3. Fluorescence was 
also greatest in the kidneys at day 7: 4.5 times greater for A-MNPs and 3.7 times greater 
than the heart for C-MNPs. Combined fluorescence and computed tomography (CT) 
imaging focused solely on the kidneys of a mouse treated with A-MNPs confirmed kidney 
localization as well as relatively even distribution throughout the kidneys (Figure 3c,d, 
Supporting Information Movie S1). Thus, surface charge did not significantly affect the 
biodistribution of these nanoparticles, which may be explained by the finding that incubation 
in FBS caused the ζ-potentials of A-MNP and C-MNP nanoparticles to become very similar 
(Figure 2d). We also measured the biodistribution of neutral (ζ-potential = 0.38 mV) 
mesoscale nanoparticles (N-MNPs), synthesized with methoxy-PEG (mPEG), (Supporting 
Information Figure S4). These particles, 328.1 nm in diameter, similarly localized 
preferentially in the kidneys and exhibited 6.7 times more fluorescence than the next-
brightest organ, the lungs. We confirmed that surface PEGylation is necessary for kidney 
localization by determining the biodistribution of non- PEGylated PLGA opsonizing 
nanoparticles (O-MNPs) with a diameter of 327.1 nm and an anionic surface (−18.1 mV) 
(Supporting Information Figure S5). These particles primarily localized to the liver 30 min 
following intravenous injection and appeared to clear by hepatobiliary excretion at 4 h, 
which we concluded from the nanoparticle localization in the large intestine at this time 
point. This result correlates with previous research demonstrating that opsonizing 
nanoparticles are endocytosed by Kupffer cells within the liver within seconds of 
injection.48–50 We detected little organ fluorescence above background after 1 day and none 
after 3 days; thus, surface PEGylation is also necessary for long-term degradation and 
controlled payload release from the particles, as has been previously described.18,50 
Therefore, MNP kidney targeting appears to depend predominantly on size and surface 
functionalization but is independent of moderate surface charges.
Fluorescence imaging in live mice underestimates signal in the kidneys, heart, and other 
dense tissues compared to ex vivo quantification.45,51,52 To investigate this difference, we 
imaged the mouse carcass following organ removal, which revealed a significant decrease in 
fluorescent foci discussed above (Supporting Information Figure S6a). We determined that 
the extent to which in vivo imaging underestimates kidney fluorescence is 25–30 times, 
compared to 2.0–3.5 times for the lungs (Supporting Information Figure S6b).
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In order to provide higher order spatial information regarding the distribution of 
nanoparticles in the kidney, we used both immunofluorescence (IF) and 
immunohistochemistry (IHC) techniques. Kidney tissue from treated or control mice was 
sectioned and stained for CD31 (blood vessels) or E-cadherin (distal tubules) expression by 
IF and for the presence of PEG by IHC. Nanoparticle fluorescence in the renal tubules of 
MNP-treated mice was significantly higher than negative controls (Figure 4a–c, Supporting 
Information Figure S7). Furthermore, the fluorescence was brighter in proximal tubules 
compared to distal tubules as revealed by costaining for E-cadherin, a marker of distal 
tubules (Figure 4a,b,g, Supporting Information Figure S7).53,54 This tissue distribution 
pattern was confirmed by antibody staining for PEG (Figure 4e, Supporting Information 
Figure S9). Thus, colocalized fluorescence from MNPs and staining for the nanoparticle 
surface confirmed that both the polymer and the encapsulated dye cargo are present in the 
proximal tubules. Interestingly, there was negligible particle localization in the endothelium 
or mesangial cells in the glomeruli as determined by IF and IHC (Figure 4d,f, Supporting 
Information Figures S6 and S9). The fluorescence staining intensity was greater at the 
basolateral side of the epithelial cells (Figure 4c,h, Supporting Information Figures S7 and 
8). In vivo fluorescence dissipated over time (Supporting Information Figure S3), indicating 
that MNPs target and release payload in a controlled manner in the proximal tubules.
Nanoparticles that selectively and stably localize to the kidneys are relatively rare in the 
literature (Figure 1). We investigated the parameters necessary to effect localization toward 
the kidneys and away from other organs such as the liver and spleen. The role of 
nanoparticle size with respect to the organ of localization is not clear. Also, it is apparent 
from this study that a relatively small surface charge, or lack thereof, does not significantly 
affect biodistribution because A-MNPs, C-MNPs, and N-MNPs all localized in the kidneys. 
Our findings, in agreement with the literature (Figure 1), suggest that the most important 
factor for directing nanoparticles to organs other than the liver and spleen is a relatively 
nonopsonizing surface. To this end, Owens and Peppas have suggested that longer PEG 
chains (>2000 Da) are the most effective at reducing opsonization.3 Additionally, PEG 
surface coverage greater than 2% is important.55 MNPs have 5000 Da PEG chains and a 
PEG/PLGA weight ratio of 9–13%, suggesting that they will significantly reduce 
opsonization. Our MNPs have a similar PEG chain size with PEG/PLGA ratios in 
approximately the same range as others in the literature (Figure 1).
We next probed the mechanism of localization to the kidney at the tissue level. By histology, 
we showed MNPs predominantly localized in the basolateral region of proximal tubule 
epithelial cells. Previous work showed that nanoparticles of approximately 80 nm in 
diameter with a nonopsonizing surface targeted the kidney glomeruli.19,20 The fenestrations 
of this segment of the nephron (approximately 80–100 nm19,56) are too small for MNPs 
studied here to pass through, however. There are also fenestrations in the peritubular 
capillaries which run along the renal tubules; however those are also reportedly too small 
(~5 nm) for passage of MNPs.21 Thus, we propose that our particles were endocytosed by 
endothelial cells of the peritubular capillaries, which we show to occur in vitro and has been 
studied previously (Supporting Information Figure S9).57 It is likely that MNPs are 
endocytosed to a greater extent by peritubular endothelial cells than glomerular endothelial 
cells due to the sharp drop in pressure in this segment of the nephron (50–10 mmHg) and the 
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large absorptive pressure of peritubular capillaries that allows the particles greater 
opportunity to interact with capillary endothelial cell membranes.56,58 We propose that 
MNPs are transcytosed across the thin (<500 nm) endothelial cells, as has previously been 
described for capillary endothelial cells59,60 and released into the tubulointerstitium between 
the capillary and epithelial cells of the tubule. The MNPs would likely then be endocytosed 
by epithelial cells of the tubule; we showed that this occurs in vitro, as previously shown 
(Supporting Information Figure S10).61 In these renal epithelial cells, the nanoparticles were 
retained for days to weeks in mice before degradation. Previous work has shown that PLGA 
nanoparticles avoid endolysosomal degradation and become associated with the 
endoplasmic reticulum and Golgi after endocytic uptake,61 potentially increasing the utility 
of MNPs for drug delivery in the treatment of diseases affecting the proximal tubules.
In this work, we synthesized and studied a class of polymeric mesoscale nanoparticles that 
selectively and stably localized in the proximal tubule epithelium of the kidneys. Exploring 
the parameter spaces responsible for kidney targeting, we found that a low opsonization 
potential was very important, but moderate changes in zeta potential had no effect on 
localization. We propose a potential mechanism of localization to the proximal tubules 
supported by histological evidence whereby the nanoparticles are endocytosed by 
endothelial cells of the peritubular capillaries because of the pressure drop in the nephron 
and the large absorptive pressure of the capillaries. However, further study of the 
physiological mechanism of tissue localization is warranted. This targeting strategy may be 
applicable to the treatment of diseases that affect the proximal tubules and as a tool for 
studying renal physiology.
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Nanoparticle localization reported in the literature. The primary organ of localization for 
nontargeted nanoparticles administered intravenously to healthy mice was plotted according 
to the particle diameter and degree of surface passivation. Numbers correlate with literature 
references listed in Supporting Information Table S1 while the red dash symbol denotes A-
MNPs, red plus symbol denotes C-MNPs particles, red star denotes N-MNPs, and black 
dashed circle denotes O-MNPs synthesized in this study. Black references denote liver 
localization, blue denotes spleen, red denotes the kidneys, and orange denotes other 
(stomach or lymph nodes).
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MNP characterization. Scanning electron micrographs of (A) A-MNPs and (B) C-MNPs. 
Scale bars are 300 nm for both images. (C) Dynamic nanoparticle stability measurement by 
DLS in phosphate-buffered saline (PBS) and fetal bovine serum (FBS). (D) Nanoparticle ζ-
potentials in water and FBS. (E) Nanoparticle dye release assay in PBS and FBS.
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In vivo biodistribution of MNPs. (A) Dorsal image of mice treated with PBS, 50 mg/kg A-
MNPs, 50 mg/kg C-MNPs, and an equal molar weight of free dye on the day they were 
sacrificed. (B) Ex vivo organ fluorescence from mice injected with MNPs, dye, or PBS 
normalized by total organ weight (mean ± SD). (C) Fluorescence plus CT overlay focused 
on the kidneys of a mouse treated with A-MNPs showing localization and relatively 
homogeneous distribution throughout the kidneys. (D) Fluorescence plus CT transaxial 
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section of a mouse treated with A-MNPs showing bright fluorescence throughout the 
kidneys.
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Tissue-level localization of MNPs. Representative micrographs of renal tissue from mice at 
day 3 after nanoparticle administration. (A–D) Immunofluorescence images with blue 
denoting DAPI stain for cell nuclei and red denoting fluorescence from nanoparticles 
(excluding bright red blood cells which show standard autofluorescence). Panel A shows 
fluorescence from nanoparticles and nuclei alone. B shows the same field as A, with green 
denoting E-cadherin. Green denotes CD31 in C and D. (E,F) Immunohistochemistry with 
anti-PEG antibody showing particle localization (brown). Panels A–C and E are kidney 
tubules and panels D and F are glomeruli. (G) Fluorescence quantification in proximal 
versus distal tubules for each treatment (n = 5, mean ± SD). (H) Fluorescence quantification 
in the basal portion versus apical portion of tubule epithelial cells (n = 5, mean ± SD). ***, p 
< 0.001; *, p < 0.05. All scale bars denote 10 µm.
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Table 1
Size (DLS) and Surface Charge (Zeta Potential) Data of Dye-Loaded Mesoscale Nanoparticles
nanoparticle diameter ζ potential
anionic mesoscale nanoparticle (A-MNP) 386.7 ± 18.7 nm −19.5 ± 0.6 mV
cationic mesoscale nanoparticle (C-MNP) 402.8 ± 23.4 nm 18.3 ± 1.3 mV
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